I was due to start Alemtuzumab treatment on Monday 3rd June, but got a call today from my neurologist telling me about the EMA’s Alemtuzumab safety review (Alemtuzumab safety review | Multiple Sclerosis Society UK).
While she is still prepared to prescribe it, I’m obviously nervous as the risks involved are now higher. I have been offered Ocrevus as an alternative, but I don’t know much about it as when I discussed infusion treatments with my nurse, we pretty much poo-pooed it (sorry).
I have everything in place for the treatment (work is sorted, home is sorted), and now I’m confused. I know the risks of cardiac events were 1 in 100, but now it’s higher. When do you refuse something because the risk is too high? I’ve been diagnosed for 17 years now, and I know the efficacy of DMTs is better to sooner you start them (I’ve tried many). So is it worth it?
Any advice would be gratefully received!